The company touts Verida as the world’s first detector-based spectral CT fully powered by AI. Amsterdam-based Philips unveiled the technology in December 2025.
Philips designed Verida to transform CT imaging, using AI to optimize the entire imaging chain. The company says it lowers system noise, elevates image quality and accelerates the clinical workflow.
Verida spectral CT uses PACS-native delivery and fully embeds into clinical workflow. Spectral CT measures how tissues absorb different X-ray levels, with detector-based spectral CT capable of delivering multiple spectral results from a single scan with no tradeoffs in performance or scan time.
This CT technology can offer use in radiology, interventional radiology, and cardiology. It also offers benefits in oncology as part of treatment preparation and radiation therapy planning.
Verida now integrates AI across the imaging chain, from acquisition to reconstruction. It generates industry-leading, superior spectral image quality with minimal noise, in addition to high-definition conventional images. With full AI capabilities, the system can achieve dramatic dose reduction without compromising image quality and reduce energy consumption by up to 45%.
Third-generation Nano-panel Precise dual-layer detector technology powers Verida to deliver faster, more dose-efficient reconstructions. Philips says Verida reconstructs 145 images per second, delivering entire exams automatically in less than 30 seconds. That represents twice the speed of previous offerings, enabling up to 270 exams every day. It builds on Philips’ proprietary Spectral Precise Imaging technology, using deep learning AI with advanced imaging.
Dan Xu, Business Leader of CT at Philips, said:
“With FDA clearance for Verida, we are bringing the next evolution of spectral CT to more markets. By combining always-on spectral imaging with AI-powered reconstruction, Verida enables clinicians to see more, first time right, supporting faster, more informed decisions and expanding the role of CT across clinical pathways.”
